Table 2.
Systemic IL-12. TNF-a. and NOx levels according to clinicopathological data.
| Pars meter | Subgroups | Exposed | Unexposed | p-value | Exposed | Unexposed | p-value | Exposed | Unexposed | p-VHlue |
|---|---|---|---|---|---|---|---|---|---|---|
| Age at diagnosis (years) | < 40 | 26.84 (19.5–38.64 | 24.6 (5.67–42.79 | 0.76 | 89.3 (33.9–67.9) | 120.22 (19.33–203.57) | 0.61 | 36.76 (26.33 –118.72) | 41.76 (26.33–75.89) | 0.83 |
| 40–60 | 20.45 (9.28– 143.52) | 29.36 (13.75 (190.86) | 0.02* | 87.9(0.0–40.71) | 93.57 (16.4–83.57) | 0.6 | 32.41 (24.54–76.11) | 31.1 (7.2–160.69) | 0.76 | |
| >60 | 32.58 (5.14– 142.25) | 24.92 (13.43–133.95) | 0.95 | 117.69 (37.18–307.86) | 119.28 (59.97–172.1) | 0.78 | 31.0 (22.2–88.07) | 31.33 (8.72–129.15) | 0.77 | |
| Body mass index (Kg/m2) | < 18.5 | 27.79 (27.79–27.79) | 26.2 (26.2–26.2) | 1 | 131.45 (95.0–167.9) | 22.85 (22.65–22.85) | 3.67 | 36.76 (34.8–38.72) | 27.3 (25.02–29.59) | 0.09 |
| 18.5–24.9 | 20.77 (10.88–38.96) | 24.6 (14.39–190.86) | 0.04* | 88.6 (63.6–07.86) | 99.27 (19.36–203.57) | 0.68 | 30.68 (24.54–76.11) | 32.63 (7.63–79.8) | 0.85 | |
| > 24.9 | 22.65 (5.14 -143.32) | 27.15 (5.67–159.59) | 0.46 | 96.4 (0.0–63.6) | 104.26 (16.4–283.57) | 0.23 | 33.24 (22.2–118.72) | 31.54 (7.2–160 89) | 0.66 | |
| Menopause at diagnosis | Yes | 22.0 (5.14–143.32) | 26.84 (13.43–190.86) | 0.41 | 99.74 (0.0–07.86) | 110.7 (16.4–172.1) | 0.74 | 31.98 (22.2–88 07) | 31.87 (7.2–160.89) | 0.56 |
| No | 25.72 (10.88–51.0) | 27.15 (5.67–159.59) | 0.05* | 86.45 (12.21 –167.9) | 93.57 (19.36–283.57) | 0.56 | 33.7 (25.63–118.72) | 29.8 (7.63–75.89) | 0.71 | |
| Molecular subtype | Lumina A | 22.0 (10.88–143.52) | 41.38 (13.43–190.86) | 0.15 | 97.86 (0.0–63.6) | 106.4 (36.4–46.4) | 0.87 | 32.2 (25.24–66.96) | 29.48 (7.2–67.59) | 0.24 |
| Luminal Li | 22.69 (10.88–142.25) | 27.15 (5.67–159.59) | 0.18 | 93.6 (12.21–67.9) | 99.04(19.33–283.57) | 0.48 | 34.76 (22.2–76.11) | 34.15 (7.63–160.89) | 0.53 | |
| HER2-amplified | 20.77 (15.67–23.64) | 19.81 (19.5–20.13) | 0.94 | 118.56 (73.57–307.86) | 119.3 (93.57–203.57) | 0.74 | 30.46 (25.63–70.67) | 30.24 (26.11 –75.89) | 0.24 | |
| Triple-negative | 27.8 (5.14–55.56) | 19.18 (14.71 –37.0) | 0.5 | 89.3 (33.6–137.86) | 97.9 (16.4–52.1) | 0.85 | 32.63 (24.76–118.72) | 33.61 (25.67–102.2) | 0.99 | |
| Tumor grade | I | 22.0 (5.14141.5) | 28.43 (5.67–190.86) | 0.08 | 100.73 (0.0–33.57) | 135.95 (39.45–203.57) | 0.19 | 34.04 (24.54–88.07) | 28.82 (7.2–160.89) | 0.74 |
| II | 26.84 (10.88–143.52) | 27.6 (13.43133.95) | 0.45 | 81.45 (21.87–307.86) | 100.19 (39.3–283.57) | 0.54 | 31.98 (22.2–118.72) | 37.03 (10.02–129 15) | 0.21 | |
| III | 27.79 (19.82 –38.64) | 26.52 (14.71 -159.59) | 0.5 | 136.4 (12.21–167.9) | 96.82 (16.4–52.1) | 0.55 | 34.35 (27.35–73.5) | 30.02 (24.37 -102.2) | 0.65 | |
| Lymph node metastasis | No | 25.24 (5.14–142.25) | 26.36 (5.67–137.78) | 0.46 | 81.45 (12.21–67.9) | 133.1 (22.85–283.57) | 0.1 | 31.11 (22.2–65.89) | 30.24 (7.63–129.15) | 0.43 |
| Yes | 21.09 [9.28–143 52) | 27.15 (13.43–190.86) | 0.14 | 103.6 (0.0–307.86) | 97.58 (16.4–03.57) | 0.48 | 33.26 (24.54–118.72) | 32 2 (7.2 160.89) | 0.77 |
*Statistical significance